Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097

Clinical Cancer Research

Volumn 18, Issue 7, 2012, Pages 2066-2079

  Wu, Jianmei ^a   LoRusso, Patricia M ^a   Matherly, Larry H ^a   Li, Jing ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; GAMMA SECRETASE INHIBITOR; OROSOMUCOID; PLASMA PROTEIN; RO 4929097; UNCLASSIFIED DRUG; VISMODEGIB;

AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INHIBITION; DRUG POTENTIATION; DRUG PROTEIN BINDING; EQUILIBRIUM DIALYSIS; FRACTION UNBOUND; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEINASE INHIBITION; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ALGORITHMS; AMYLOID PRECURSOR PROTEIN SECRETASES; ANILIDES; ANIMALS; AREA UNDER CURVE; BENZAZEPINES; BINDING, COMPETITIVE; BLOOD PROTEINS; BREAST NEOPLASMS; DRUG INTERACTIONS; FEMALE; HUMANS; KINETICS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; OROSOMUCOID; PROTEIN BINDING; PYRIDINES;

EID: 84859402075     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2684     Document Type: Article

References (29)

1. Tien AC, Rajan A, Bellen HJ. A Notch updated. J Cell Biol 2009;184:621-9.
2. Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell 2009;16:633-47.
3. Dufraine J, Funahashi Y, Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008;27:5132-7.
4. Baldi A, De Falco M, De Luca L, Cottone G, Paggi MG, Nickoloff BJ, et al. Characterization of tissue specific expression of Notch-1 in human tissues. Biol Cell 2004;96:303-11. (Pubitemid 38618758)
5. Shih Ie M, Wang TL. Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007;67:1879-82.
6. Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, et al. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 2009;69:7672-80.
7. Tolcher A, Mikulski S, Messersmith W, Kwak E, Gibbon D, Boylan J, et al. A phase I study of RO4929097, a novel gamma secretase inhibitor, in patients with advanced solid tumors. J Clin Oncol 28:15s, 2010 (suppl; abstr 2502).
8. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002;71:115-21. (Pubitemid 34271114)
9. Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999;59:1454-7. (Pubitemid 29160110)
10. Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S, et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003;9:625-32. (Pubitemid 36182594)
11. Fuse E, Tanii H, Takai K, Asanome K, Kurata N, Kobayashi H, et al. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans. Cancer Res 1999;59:1054-60. (Pubitemid 29135966)
12. Li J, Brahmer J, Messersmith W, Hidalgo M, Baker SD. Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. Invest New Drugs 2006;24:291-7.
13. Wu J, Wiegand R, Lorusso P, Li J. Validation and implementation of a liquid chromatography/tandem mass spectrometry assay for quantitation of the total and unbound RO4929097, a gamma-secretase inhibitor targeting Notch signaling, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:1537-43.
14. Wiegand R, Wu J, Sha X, LoRusso P, Li J. Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:333-9.
15. Ding X, Chou B, Graham RA, Cheeti S, Percey S, Matassa LC, et al. Determination of GDC-0449, a small-molecule inhibitor of the Hedgehog signaling pathway, in human plasma by solid phase extraction-liquid chromatographic-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2010;878:785-90.
16. Larson Gedman A, Chen Q, Kugel Desmoulin S, Ge Y, LaFiura K, Haska CL, et al. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia 2009;23:1417-25.
17. Rowland M, Tozer T. Blood-to-plasmaconcentration ratio. In: Rowland M, Tozer T, editors. Clinical pharmacokinetics: concepts and applications. Philadelphia, PA: Williams & Wilkins; 1995. p. 502-3.
18. Kremer JM, Wilting J, Janssen LH. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988;40:1-47.
19. Duche JC, Urien S, Simon N, Malaurie E, Monnet I, Barre J. Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer. Clin Biochem 2000;33:197-202. (Pubitemid 30489064)
20. Graham RA, Lum BL, Cheeti S, Jin JY, Jorga K, Von Hoff DD, et al. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res 2011;17:2512-20.
21. Tomei L, Eap CB, Baumann P, Dente L. Use of transgenic mice for the characterization of human alpha 1-acid glycoprotein (orosomucoid) variants. Hum Genet 1989;84:89-91. (Pubitemid 20022435)
22. Yuasa I, Umetsu K, Vogt U, Nakamura H, Nanba E, Tamaki N, et al. Human orosomucoid polymorphism: molecular basis of the three common ORM1 alleles, ORM1*F1, ORM1*F2, and ORM1*S. Hum Genet 1997;99:393-8. (Pubitemid 27095804)
23. Tinguely D, Baumann P, Conti M, Jonzier-Perey M, Schopf J. Interindividual differences in the binding of antidepressives to plasma proteins: the role of the variants of alpha 1-acid glycoprotein. Eur J Clin Pharmacol 1985;27:661-6. (Pubitemid 15167087)
24. Herve F, Caron G, Duche JC, Gaillard P, Abd Rahman N, Tsantili-Kakoulidou A, et al. Ligand specificity of the genetic variants of human alpha1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant. Mol Pharmacol 1998;54:129-38.
25. Fitos I, Visy J, Zsila F, Mady G, Simonyi M. Selective binding of imatinib to the genetic variants of human alpha1-acid glycoprotein. Biochim Biophys Acta 2006;1760:1704-12.
26. Colombo S, Buclin T, Decosterd LA, Telenti A, Furrer H, Lee BL, et al. Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clin Pharmacol Ther 2006;80:307-18. (Pubitemid 44479747)
27. Barrail-Tran A, Mentre F, Cosson C, Piketty C, Chazallon C, Gerard L, et al. Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial. Antimicrob Agents Chemother 2010;54:614-9.
28. Wilkinson GR. Plasma and tissue binding considerations in drug disposition. Drug Metab Rev 1983;14:427-65. (Pubitemid 13077088)
29. Giannetti AM, Wong H, Dijkgraaf GJ, Dueber EC, Ortwine DF, Bravo BJ, et al. Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449). J Med Chem 2011;54:2592-601.